Panic Disorders

Also known as: Panic disorder / [X]Panic disorder [episodic paroxysmal anxiety] / Panic disorder NOS

DrugDrug NameDrug Description
DB00404AlprazolamAlprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[Label] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[Label] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms.[A18125] Alprazolam's adverse effects are generally related to the sedation it can cause.[A18125] Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death.[A18125] Alprazolam was given FDA approval on October 16, 1981[L6148].
DB00215CitalopramCitalopram belongs to a class of antidepressant agents known as selective _serotonin-reuptake inhibitors_ (SSRIs) and is widely used to treat the symptoms of depression. Its chemical structure is unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other prescribed antidepressants [FDA label]. Citalopram is also known as _Celexa_, and available in tablet and solution forms [FDA label]. This drug was initially approved by the FDA in 1998 [L5230].
DB01242ClomipramineClomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine.
DB01068ClonazepamA benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop [FDA Label] [L5572, F3763, F3787, F3796]. The agent has also been indicated for treating panic disorder [FDA Label] [A175438, L5572, F3763, F3787, F3796]. The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses [FDA Label] [A175438, A175441, L5572, F3763, F3787, F3796]. Since being first patented in 1960 and then released for sale from Roche in the US in 1975 [T469, T472], clonazepam has experienced a storied history in the treatment of the aforementioned medical conditions. Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. Unfortunately, however, like most benzodiazepines, clonazepam use has also been associated with recreational use and drug abuse [FDA Label] [L5572, F3763, F3787, F3796].
DB01151DesipramineDesipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).
DB01175EscitalopramEscitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Escitalopram may be used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD).
DB00458ImipramineImipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as imipramine and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively [A6584]. Imipramine has less sedative and anticholinergic effects than the tertiary amine TCAs, amitriptyline and clomipramine. Imipramine may be used to treat depression and nocturnal enuresis in children [FDA Label]. Unlabeled indications include chronic and neuropathic pain (including diabetic neuropathy), panic disorder, attention-deficit/hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD) [L1349,L1348,A31900,L1351,L1352,L1353,A31904].
DB00186LorazepamLorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic.[A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095]
DB00370MirtazapineMirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994.[A177946] This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.[A177811]
DB00715ParoxetineParoxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others.[T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters.[A31914] Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class.[A31914] The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
DB01104SertralineSertraline hydrochloride belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake [T28]. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a more detailed listing of side effects). Compared to other agents in this class, sertraline may cause greater diarrheal and male sexual dysfunction effects [A1844]. Sertraline displays a better safety or tolerability profile than other classes of antidepressants [A1846]. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants or monoamine oxidase inhibitors [T28]. Sertraline has shown therapeutic effectiveness as a treatment for major depressive disorder [A1836], obsessive-compulsive disorder (OCD) [A1838], panic disorder, post-traumatic stress disorder (PTSD) [A1841], premenstrual dysphoric disorder (PMDD) [A1842] and social anxiety disorder (social phobia).
DB00285VenlafaxineVenlafaxine (Effexor) is an antidepressant within the serotonin-norepinephrine reuptake inhibitor (SNRI) class of medications. It exerts its effects primarily by blocking the transporters involved in the reuptake of the neurotransmitters serotonin and norepinephrine, therefore leaving more active neurotransmitter in the synapse. Venlafaxine is officially approved for use in the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder. As of 2014, Canadian clinical practice guidelines recommend venlafaxine as a first-line option for treatment of generalized anxiety, social anxiety, panic disorder, major depressive disorder (MDD), and consider it a second-line option for management of obsessive-compulsive disorder (OCD) [A177226, A177235]. Venlafaxine is also used off-label for prophylaxis of migraine headaches [A177229], for reduction of vasomotor symptoms associated with menopause [A177238], and for management of neuropathic pain (although there is only minimal evidence of efficacy for this condition) [A177232].
DrugDrug NameTargetType
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-1target
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-6target
DB00404AlprazolamTranslocator proteintarget
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-3target
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-4target
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-5target
DB00404AlprazolamGamma-aminobutyric acid receptor subunit alpha-2target
DB00404AlprazolamCytochrome P450 3A4enzyme
DB00404AlprazolamCytochrome P450 2C9enzyme
DB00404AlprazolamCytochrome P450 3A5enzyme
DB00404AlprazolamCytochrome P450 3A7enzyme
DB00404AlprazolamGABA-A receptor (anion channel)target
DB00404AlprazolamSerum albumincarrier
DB00404Alprazolamalpha1-acid glycoproteincarrier
DB00215CitalopramSodium-dependent serotonin transportertarget
DB00215CitalopramCytochrome P450 2C19enzyme
DB00215CitalopramCytochrome P450 2D6enzyme
DB00215CitalopramCytochrome P450 3A4enzyme
DB00215CitalopramMultidrug resistance protein 1transporter
DB00215CitalopramCytochrome P450 1A2enzyme
DB00215CitalopramHistamine H1 receptortarget
DB01242ClomipramineSodium-dependent serotonin transportertarget
DB01242ClomipramineSodium-dependent noradrenaline transportertarget
DB01242ClomipramineGlutathione S-transferase Ptarget
DB01242Clomipramine5-hydroxytryptamine receptor 2Atarget
DB01242ClomipramineCytochrome P450 1A2enzyme
DB01242ClomipramineCytochrome P450 2D6enzyme
DB01242ClomipramineCytochrome P450 2C19enzyme
DB01242ClomipramineMultidrug resistance protein 1transporter
DB01242ClomipramineCytochrome P450 3A4enzyme
DB01242Clomipramine5-hydroxytryptamine receptor 2Btarget
DB01242Clomipramine5-hydroxytryptamine receptor 2Ctarget
DB01242ClomipramineSerum albumincarrier
DB01068ClonazepamTranslocator proteintarget
DB01068ClonazepamCytochrome P450 3A4enzyme
DB01068ClonazepamSerum albumincarrier
DB01068ClonazepamCytochrome P450 2E1enzyme
DB01068ClonazepamArylamine N-acetyltransferase 2enzyme
DB01068ClonazepamGABA-A receptor (anion channel)target
DB01068ClonazepamNuclear receptor subfamily 1 group I member 2target
DB01151DesipramineMuscarinic acetylcholine receptor M1target
DB01151DesipramineSodium-dependent noradrenaline transportertarget
DB01151DesipramineBeta-2 adrenergic receptortarget
DB01151DesipramineMuscarinic acetylcholine receptor M2target
DB01151DesipramineSodium-dependent serotonin transportertarget
DB01151DesipramineHistamine H1 receptortarget
DB01151DesipramineBeta-1 adrenergic receptortarget
DB01151DesipramineCytochrome P450 2D6enzyme
DB01151DesipramineMuscarinic acetylcholine receptor M3target
DB01151DesipramineMuscarinic acetylcholine receptor M4target
DB01151DesipramineMuscarinic acetylcholine receptor M5target
DB01151DesipramineAlpha-1 adrenergic receptorstarget
DB01151Desipramine5-hydroxytryptamine receptor 2Atarget
DB01151DesipramineAlpha-1-acid glycoprotein 1carrier
DB01151DesipramineCytochrome P450 2B6enzyme
DB01151DesipramineCytochrome P450 3A4enzyme
DB01151DesipramineSolute carrier family 22 member 2transporter
DB01151DesipramineSolute carrier family 22 member 1transporter
DB01151DesipramineSolute carrier family 22 member 3transporter
DB01151DesipramineSolute carrier family 22 member 5transporter
DB01151DesipramineMultidrug resistance protein 1transporter
DB01151DesipramineSolute carrier family 22 member 4transporter
DB01151DesipramineCytochrome P450 1A2enzyme
DB01151DesipramineCytochrome P450 2A6enzyme
DB01151DesipramineCytochrome P450 2C19enzyme
DB01151DesipramineCytochrome P450 2E1enzyme
DB01151DesipramineSphingomyelin phosphodiesterasetarget
DB01151Desipramine5-hydroxytryptamine receptor 1Atarget
DB01151Desipramine5-hydroxytryptamine receptor 2Ctarget
DB01151DesipramineD(2) dopamine receptortarget
DB01151DesipramineAlpha-2 adrenergic receptorstarget
DB01175EscitalopramSodium-dependent serotonin transportertarget
DB01175EscitalopramCytochrome P450 3A4enzyme
DB01175EscitalopramCytochrome P450 2D6enzyme
DB01175EscitalopramSodium-dependent dopamine transportertarget
DB01175EscitalopramSodium-dependent noradrenaline transportertarget
DB01175EscitalopramAlpha-1A adrenergic receptortarget
DB01175EscitalopramMuscarinic acetylcholine receptor M1target
DB01175EscitalopramHistamine H1 receptortarget
DB01175EscitalopramCytochrome P450 2C19enzyme
DB00458ImipramineSodium-dependent noradrenaline transportertarget
DB00458ImipramineSodium-dependent serotonin transportertarget
DB00458ImipramineCytochrome P450 1A2enzyme
DB00458ImipramineCytochrome P450 2C19enzyme
DB00458ImipramineCytochrome P450 2D6enzyme
DB00458ImipramineHistamine H1 receptortarget
DB00458ImipramineAlpha-1A adrenergic receptortarget
DB00458Imipramine5-hydroxytryptamine receptor 2Atarget
DB00458ImipramineMuscarinic acetylcholine receptor M1target
DB00458ImipramineMuscarinic acetylcholine receptor M2target
DB00458ImipramineMuscarinic acetylcholine receptor M3target
DB00458ImipramineMuscarinic acetylcholine receptor M4target
DB00458ImipramineMuscarinic acetylcholine receptor M5target
DB00458ImipraminePotassium voltage-gated channel subfamily D member 2target
DB00458ImipraminePotassium voltage-gated channel subfamily D member 3target
DB00458ImipramineAlpha-1D adrenergic receptortarget
DB00458ImipramineAlpha-1-acid glycoprotein 1carrier
DB00458ImipramineSolute carrier family 22 member 2transporter
DB00458ImipramineSolute carrier family 22 member 3transporter
DB00458ImipramineMultidrug resistance protein 1transporter
DB00458ImipramineSolute carrier family 22 member 4transporter
DB00458ImipramineCytochrome P450 3A4enzyme
DB00458ImipramineCytochrome P450 2B6enzyme
DB00458ImipramineCytochrome P450 2C18enzyme
DB00458ImipramineCytochrome P450 2E1enzyme
DB00458ImipramineCytochrome P450 3A7enzyme
DB00458Imipramine5-hydroxytryptamine receptor 2Ctarget
DB00458ImipramineAlpha-1B adrenergic receptortarget
DB00458Imipramine5-hydroxytryptamine receptor 7target
DB00458ImipramineD(1) dopamine receptortarget
DB00458ImipramineD(2) dopamine receptortarget
DB00458ImipraminePotassium voltage-gated channel subfamily H member 2target
DB00458ImipramineSodium-dependent dopamine transportertarget
DB00458Imipramine5-hydroxytryptamine receptor 1Atarget
DB00458Imipramine5-hydroxytryptamine receptor 6target
DB00458ImipraminePotassium voltage-gated channel subfamily H member 1target
DB00458ImipramineSerum albumincarrier
DB00458ImipramineAlpha-1-acid glycoprotein 2target
DB00186LorazepamTranslocator proteintarget
DB00186LorazepamUDP-glucuronosyltransferase 2B15enzyme
DB00186LorazepamGABA-A receptor (anion channel)target
DB00186LorazepamCytochrome P450 3A4enzyme
DB00370Mirtazapine5-hydroxytryptamine receptor 2Atarget
DB00370Mirtazapine5HT3 serotonin receptortarget
DB00370MirtazapineAlpha-2A adrenergic receptortarget
DB00370Mirtazapine5-hydroxytryptamine receptor 2Ctarget
DB00370MirtazapineKappa-type opioid receptortarget
DB00370MirtazapineHistamine H1 receptortarget
DB00370MirtazapineCytochrome P450 1A2enzyme
DB00370MirtazapineCytochrome P450 3A4enzyme
DB00370MirtazapineCytochrome P450 2D6enzyme
DB00370MirtazapineAlpha-1 adrenergic receptorstarget
DB00370MirtazapineSodium-dependent serotonin transportertransporter
DB00715ParoxetineSodium-dependent serotonin transportertarget
DB00715ParoxetineSodium-dependent noradrenaline transportertarget
DB00715Paroxetine5-hydroxytryptamine receptor 2Atarget
DB00715ParoxetineCytochrome P450 2D6enzyme
DB00715ParoxetineCytochrome P450 2C9enzyme
DB00715ParoxetineMultidrug resistance protein 1transporter
DB00715ParoxetineCytochrome P450 2B6enzyme
DB00715ParoxetineCytochrome P450 1A2enzyme
DB00715ParoxetineCytochrome P450 3A4enzyme
DB00715ParoxetineAlpha-1 adrenergic receptorstarget
DB00715ParoxetineAlpha-2 adrenergic receptorstarget
DB00715ParoxetineBeta adrenergic receptortarget
DB00715ParoxetineD(2) dopamine receptortarget
DB00715ParoxetineHistamine H1 receptortarget
DB00715ParoxetineSerotonin Receptorstarget
DB00715ParoxetineMuscarinic acetylcholine receptortarget
DB00715Paroxetine5-hydroxytryptamine receptor 2Btarget
DB00715ParoxetineD(1) dopamine receptortarget
DB00715ParoxetineCytochrome P450 2C19enzyme
DB01104SertralineSodium-dependent serotonin transportertarget
DB01104SertralineCytochrome P450 2B6enzyme
DB01104SertralineCytochrome P450 2C19enzyme
DB01104SertralineCytochrome P450 2C9enzyme
DB01104SertralineCytochrome P450 2D6enzyme
DB01104SertralineSodium-dependent dopamine transportertarget
DB01104SertralineCYP2B proteinenzyme
DB01104SertralineCytochrome P450 3A4enzyme
DB01104SertralineAmine oxidase [flavin-containing] Benzyme
DB01104SertralineAmine oxidase [flavin-containing] Aenzyme
DB01104SertralineMultidrug resistance protein 1transporter
DB01104SertralineSerum albumincarrier
DB01104SertralineSigma receptortarget
DB00285VenlafaxineSodium-dependent serotonin transportertarget
DB00285VenlafaxineSodium-dependent noradrenaline transportertarget
DB00285VenlafaxineCytochrome P450 2D6enzyme
DB00285VenlafaxineCytochrome P450 3A4enzyme
DB00285VenlafaxineSodium-dependent dopamine transportertarget
DB00285VenlafaxineMultidrug resistance protein 1transporter
DB00285VenlafaxineATP-binding cassette sub-family G member 2transporter
DrugDrug NamePhaseStatusCount
DB00715Paroxetine1Completed1
DB00404Alprazolam2Completed1
DB00260Cycloserine2Completed1
DB01202Levetiracetam2Completed1
DB12220ORG-259352Terminated1
DB00715Paroxetine2Terminated1
DB00571Propranolol2Not Yet Recruiting1
DB00734Risperidone2Terminated1
DB01068Clonazepam2 / 3Completed1
DB01104Sertraline2 / 3Completed1
DB00260Cycloserine3Terminated1
DB01202Levetiracetam3Completed1
DB00715Paroxetine3Completed1
DB00285Venlafaxine3Completed3
DB00404Alprazolam4Completed3
DB00404Alprazolam4Terminated3
DB01238Aripiprazole4Completed1
DB01068Clonazepam4Completed1
DB00363Clozapine4Completed1
DB00476Duloxetine4Completed1
DB01175Escitalopram4Completed2
DB01175Escitalopram4Recruiting1
DB00422Methylphenidate4Recruiting1
DB00715Paroxetine4Completed5
DB01224Quetiapine4Completed2
DB00734Risperidone4Completed1
DB01104Sertraline4Completed2
DB01104Sertraline4Terminated1
DB09034Suvorexant4Active Not Recruiting1
DB00313Valproic acid4Unknown Status1
DB09068Vortioxetine4Completed1
DB00246Ziprasidone4Completed1
DB00260CycloserineNot AvailableCompleted1
DB00476DuloxetineNot AvailableActive Not Recruiting1
DB01175EscitalopramNot AvailableTerminated1
DB00472FluoxetineNot AvailableActive Not Recruiting1
DB00458ImipramineNot AvailableCompleted1
DB01064IsoprenalineNot AvailableRecruiting1
DB00715ParoxetineNot AvailableActive Not Recruiting1
DB00715ParoxetineNot AvailableCompleted3
DB00715ParoxetineNot AvailableUnknown Status1
DB01224QuetiapineNot AvailableCompleted1
DB00980RamelteonNot AvailableTerminated1
DB00734RisperidoneNot AvailableCompleted1
DB01104SertralineNot AvailableCompleted3
DB09153Sodium chlorideNot AvailableRecruiting1
DB00285VenlafaxineNot AvailableActive Not Recruiting1